Excipient Manufacturer Site Change and Nitrosamine Risk

The lots should not be released on the certificate of analysis alone. A change of manufacturing site is a significant supplier change even if the specification is unchanged. The approved supplier list does not cover the new site, the notification was late, and there has been no audit in five years. Release would bypass the site's own supplier qualification procedure.

Required actions include: place the lots on hold under a supplier change control; request the supplier's site master file, process flow, equipment and water data, and change justification; perform a documented risk assessment for the three products; review whether the new site is already approved for any other material; and conduct an audit or a documented remote assessment. Additional testing should be risk-based, including identity plus at least one site-specific impurity or performance-related attribute. If the risk assessment and data show equivalence, QA may release with a justification and a plan for ongoing monitoring. If not, reject or return the lots. The 30-day notification breach should be handled as a supplier quality issue, with a corrective action request and a review of the quality agreement.

Nitrosamine risk is not limited to the active ingredient. The assessment should examine the binder's chemical structure, raw materials, solvents, catalysts, water, and equipment for secondary or tertiary amines and nitrosating agents. It should also consider the new site's process, utilities, cleaning procedures, and potential cross-contamination. The three products, especially the extended-release tablet, should be screened for nitrosamine formation or carryover. If a theoretical risk exists, confirmatory testing with a validated method and an appropriate limit is needed.

Regulatory notification depends on the jurisdiction and the product's marketing authorization. A site change may require a variation or prior approval, and a nitrosamine risk assessment may need to be submitted. The quality unit should not assume that a supplier certificate resolves the obligation. The site should document the assessment, notify the relevant authority if required, and update the marketing authorization file. If a nitrosamine is detected above the acceptable limit, the batch should be rejected and a recall assessment initiated. The decision should be made with regulatory affairs and QA.

The site needs a supplier change-control clause that requires notification before shipment, not after. The quality agreement should define what constitutes a change, the notification period, data requirements, audit rights, and consequences for noncompliance. The approved supplier list should be site-specific, not just supplier-specific. Incoming testing should be based on risk and include periodic full testing or reduced testing with justification. The site should maintain a supplier risk register and audit schedule, with more frequent audits for high-risk excipients.

Operationally, the site should use a dual-source strategy or safety stock for critical excipients, and the change control should require regulatory, quality control, and production sign-off. Supplier scorecards should track late notifications and quality events. The CAPA should verify that the new site is qualified before release and that the quality agreement is updated. Effectiveness can be measured by zero unapproved site changes, on-time notifications, audit closure, and no release of lots outside the approved supplier list.